Market research
QLGN Qualigen Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 18 Feb 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7M
- P/E ratio
- 1.13
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 0.28
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 7M
- P/E ratio
- 1.13
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 0.28
About
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Research context
Qualigen Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the QLGN discussion.
5 years, 6 months ago
Qualigen Therapeutics, Inc is currently in a long term downtrend where the price is trading 37.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
Qualigen Therapeutics, Inc's total revenue sank by 30.3% to $838K since the same quarter in the previous year.
Its net income has dropped by 1723.6% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 107.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Qualigen Therapeutics, Inc gets an overall score of 1/5.